Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 16/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 0.73 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | RAB9A | P51151 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | GAA | P10253 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3862485 | 0.86 | ALDH1A1 (0.74) | ALDH1A1TSHRCYP1A2CYP3A4RAB9A | |
| SCHEMBL3865559 | 0.86 | ALDH1A1 (0.74) | ALDH1A1TSHRCYP1A2CYP3A4RAB9A | |
| SCHEMBL12786989 | 0.86 | ALDH1A1 (0.75) | ALDH1A1TSHRCYP1A2CYP3A4RAB9A | |
| SCHEMBL15555582 | 0.86 | ALDH1A1 (0.75) | ALDH1A1TSHRCYP1A2CYP3A4RAB9A | |
| SCHEMBL2206756 | 0.84 | ALDH1A1 (0.73) | ALDH1A1TSHRCYP1A2CYP3A4RAB9A | |
| SCHEMBL601203 | 0.84 | ALDH1A1 (0.73) | ALDH1A1TSHRCYP1A2CYP3A4RAB9A | |
| SCHEMBL5739160 | 0.84 | ALDH1A1 (1.00) | ALDH1A1TSHRCYP1A2CYP3A4RAB9A | |
| SCHEMBL14075911 | 0.83 | ALDH1A1 (0.71) | ALDH1A1TSHRCYP1A2CYP3A4RAB9A | |
| SCHEMBL3862232 | 0.82 | ALDH1A1 (0.68) | ALDH1A1TSHRCYP1A2CYP3A4RAB9A | |
| SCHEMBL17531610 | 0.82 | ALDH1A1 (0.70) | ALDH1A1TSHRCYP1A2CYP3A4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210276956-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2021-09-09 | — | — | US | disclosed |
| US-11014906-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2021-05-25 | — | — | US | disclosed |
| CN-110540534-B | Synthetic method of organic intermediate compound | 枣庄学院 | 2020-11-13 | — | — | CN | disclosed |
| US-20200062728-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | UNIVERSITY OF SOUTH CAROLINA (US) | 2020-02-27 | — | — | US | disclosed |
| CN-110540534-A | Synthetic method of organic intermediate compound | UNIV ZAOZHUANG | 2019-12-06 | — | — | CN | disclosed |
| EP-2951158-B1 | PROCESS FOR THE PREPARATION OF IVACAFTOR AND SOLVATES THEREOF | GLENMARK PHARMACEUTICALS LTD (IN) | 2019-05-29 | — | — | EP | disclosed |
| US-10017516-B2 | BMP inhibitors and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2018-07-10 | — | — | US | disclosed |
| US-9957233-B1 | Process for preparing substituted quinolin-4-ol compounds | CALITOR SCIENCES, LLC (US) | 2018-05-01 | — | — | US | disclosed |
| US-9957233-B1 | Process for preparing substituted quinolin-4-ol compounds | CALITOR SCIENCES, LLC (US) | 2018-05-01 | — | — | US | disclosed |
| WO-2018026877-A1 | PROCESS FOR PREPARING SUBSTITUTED QUINOLIN-4-OL COMPOUNDS | CALITOR SCIENCES, LLC (US) | 2018-02-08 | — | — | WO | disclosed |
| EP-1583537-A3 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2005-12-14 | — | — | EP | disclosed |
| EP-1583537-A2 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2005-10-12 | — | — | EP | disclosed |
| EP-1578743-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2005-09-28 | — | — | EP | disclosed |
| EP-1537123-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004058144-A2 | ANTIBACTERIAL AGENTS | GLAXO GROUP LIMITED (GB) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004002992-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2004-01-08 | — | — | WO | disclosed |
| WO-2004002490-A2 | PIPERIDINE COMPOUNDS AS ANTIBACTERIALS | GLAXO GROUP LIMITED (GB) | 2004-01-08 | — | — | WO | disclosed |
| US-5506235-A | Quinoline derivatives as immunostimulants | PFIZER INC. (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0597003-A1 | QUINOLINE DERIVATIVES AS IMMUNOSTIMULANTS | PFIZER INC. (US) | 1994-05-18 | — | — | EP | disclosed |
| WO-1993003030-A1 | QUINOLINE DERIVATIVES AS IMMUNOSTIMULANTS | PFIZER INC. (US) | 1993-02-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200062728-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | CDK8, CDK9, CDK19 | ALDH1A1 4568/4885TSHR 3516/4885CYP1A2 2934/4885 |
| US-11014906-B2 | Quinoline-based compounds and methods of inhibiting CDK8/19 | CDK8, CDK9, CDK19 | ALDH1A1 4568/4885TSHR 3431/4885CYP1A2 2938/4885 |
| US-10017516-B2 | BMP inhibitors and methods of use thereof | BMP1, BMPR2, BMP2 | ALDH1A1 4531/4885TSHR 2657/4885CYP1A2 2823/4885 |
| US-20210276956-A1 | QUINOLINE-BASED COMPOUNDS AND METHODS OF INHIBITING CDK8/19 | CDK8, CDK9, CDK19 | ALDH1A1 4568/4885TSHR 3516/4885CYP1A2 2934/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.